More than Meds: Holistic Management of Obesity - Improving Health with Evidence-Based Solutions
A fireside chat with Kim Boyd, Chief Medical Officer Weight Watchers and Sebastian Meyhofer Vice President, Clinical, Medical & Regulatory Novo Nordisk.
At this year’s Health.Tech Global Summit, I had the privilege to chair a discussion between Kim Boyd, Chief Medical Officer Weight Watchers and Sebastian Meyhofer Vice President, Clinical, Medical & Regulatory Novo Nordisk. Our discussion highlighted a fundamental shift underway in how we think about and treat obesity.
For years, the conversation has been dominated by weight: kilograms lost, percentage reductions, and headline-grabbing efficacy data. But that framing is rapidly becoming outdated. The emerging consensus is that obesity is not a weight problem, it is a chronic, complex disease requiring holistic, longitudinal care.
This shift has been catalysed by the arrival of highly effective GLP-1 therapies.
These medicines are, without question, transformative. They deliver meaningful weight loss and, critically, improvements in clinical outcomes including reductions in cardiovascular events. But as powerful as they are, the discussion between Weight Watchers and Novo Nordisk made one point unequivocal - medication alone is not enough. Instead the future of obesity care lies in combination approaches integrating pharmacotherapy with nutrition, physical activity, and behavioural support.
This is not simply about enhancing weight loss; it is about improving durability, maintaining lean mass, managing side effects, and ultimately delivering better long-term health outcomes. Evidence increasingly shows that when these elements are combined, the impact extends beyond risk factor reduction to measurable reductions in disease events.
What is also becoming clear is that obesity treatment cannot be episodic. Patients do not follow a linear path. They move through phases: initiation, titration, plateau, maintenance, and sometimes re-initiation. Each phase brings different needs, from dose optimisation to behavioural reinforcement. This demands a continuous, adaptive model of care, rather than the traditional cycle of prescription and periodic review.
Digital platforms are emerging as a critical enabler of this model, a scaffold if you will, between episodic care. They allow for personalised, real-time support at scale offering guidance on adherence, side-effect management, nutrition, and lifestyle, while also fostering community and shared experience. Increasingly, these platforms will be augmented by AI, enabling more precise, responsive interventions tailored to individual patient journeys.
Alongside this, real-world evidence (RWE) is taking on a more prominent role. While randomised controlled trials remain the gold standard for efficacy, RWE is essential for understanding how therapies perform in practice across diverse populations, over longer time horizons, and within integrated care models. It will be central to demonstrating value to payers, informing health technology assessments, and shaping future care pathways.
A particularly important dimension is adherence. In current care models, patients are often left to navigate treatment largely unsupported between clinical visits. This is a critical gap. Integrated solutions that combine medication with ongoing behavioural and educational support have the potential to significantly improve adherence and, by extension, outcomes.
The discussion also pointed to a broader industry implication: GLP-1s may serve as a lighthouse for a new therapeutic paradigm. One that moves beyond the traditional “pill” to a fully integrated, patient-centred solution combining drug, data, and delivery into a cohesive care experience.
Importantly, this shift also reframes how success is measured. While percentage weight loss remains a useful metric, it is not what matters most to patients. What matters is the ability to live better: improved mobility, reduced disease burden, enhanced quality of life, and sustainable health over time. The conversation is moving at a population health level from efficacy to impact.
Finally, in an environment increasingly shaped by social media and misinformation, the need for trusted, evidence-based support systems has never been greater. Patients require reliable guidance to navigate not only treatment, but the broader lifestyle and behavioural changes that underpin long-term success.
Taken together, these themes point to a profound transformation.
GLP-1 therapies have opened the door but what comes next will define the future of obesity care.
The opportunity now is to build integrated, personalised, and scalable care models that treat obesity not as a short-term intervention, but as a lifelong condition. In doing so, the industry has a chance not only to improve individual patient outcomes, but to meaningfully shift the trajectory of global chronic disease.